NCT06495957 · NOT YET RECRUITING
Electroacupuncture for the Treatment of Agitated Symptoms of Alzheimer's Disease
This trial is testing whether electroacupuncture can reduce agitation in people who already have Alzheimer's dementia. Researchers will also use brain scans to look at how acupuncture might affect brain activity. It is a Phase NA study, meaning it is a practical clinical trial focused on effectiveness rather than a standard drug-development phase. Details on sample size and duration are limited in the source provided.
You may qualify if
- Meet the revised draft diagnostic criteria for Alzheimer's disease published by the Alzheimer's Association in 2023
- Meet the 2023 IPA definition of agitated symptoms of cognitive impairment
- Cohen Mansfield Agitation Inventory (CMAI)≥45 points
- Have been on stable anti-AD medication (cholinesterase inhibitors, etc.) for more than 1 month
- If taking antipsychotics, the medication regimen for agitation (antipsychotics) is stable for 1 month prior to randomization
- Subject and legal guardian and caregiver sign informed consent.
You're excluded if
- There are contraindications for acupuncture treatment, such as the tendency of acupoint bleeding or allergy to metal
- Received electroacupuncture treatment in the past 2 weeks
- At the time of the screening, participants are participating in other clinical trials or planned to participate in other clinical trials in the next 17 weeks.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-07-11